EP Patent

EP4233880A2 — Hnf4a sarna compositions and methods of use

Assigned to Mina Therapeutics Ltd · Expires 2023-08-30 · 3y expired

What this patent protects

The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.

USPTO Abstract

The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.

Drugs covered by this patent

lumasiran-sodium (LUMASIRAN SODIUM)

Patent Metadata

Patent number: EP4233880A2
Jurisdiction: EP
Classification: —
Expires: 2023-08-30
Drug substance claim: No
Drug product claim: No
Assignee: Mina Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.